

26

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.
PN0380

In Re Application Of: **Alan Cuthbertson, et.al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/559,886	To be assigned	To be assigned	36335	To be assigned	1550

Title: **Pharmaceutical Compounds**



Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
 PN0380

In Re Application: Alan Cuthbertson, et.al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/559,886	To be assigned	To be assigned	36335	To be assigned	1550

Title: Pharmaceutical Compounds



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. as described below.
 - Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

 (Date)

 Signature

 Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)]

 7-20-06
 (Date)

 Lori Allaire
 Signature of Person Mailing Correspondence

 Lori Allaire
 Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

 Signature

Dated:

Li Cai
 Reg. No. 45,629
 GE Healthcare, Inc.
 101 Carnegie Center
 Princeton, NJ 08540
 (609) 514-6418

CC:

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PN0380	SERIAL NO. 10/559,886
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Alan Cuthbertson, et.al.	
		FILING DATE To be assigned	GROUP To be assigned

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	98/18496	05-1998	WO				
	02/064734	08-2002	WO				
	97/10852	03-1997	WO				
	19536783A1	03-1997	DE				X
	03/051859	06-2003	WO				
	03/006491	01-2003	WO				
	03/006070	01-2003	WO				
	98/18498	05-1998	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Katugampola Sidath D, et.al. "Changes in phenotypically transformed intimal smooth muscle layer of human atherosclerotic coronary arteries" Journal of Cardiovascular Pharmacology, vol. 36, no. 5, supplement 1, 2000, pages S395-S396
	Sato Takaya, et.al., "Quantitative receptor autoradiographic analysis for angiotensin II receptors in bovine retinal microvessels: Quantitation with radioluminography" Cellular and Molecular Neurobiology, vol. 13, no. 3, 1993, pages 233-245
	Healy, D.P., et.al., "Localization of central angiotensin II receptors with Iodine-125 Sar-1 Ile-8-Angiotensin II Periventricular Sites of the Anterior Third Ventricle" Neuroendocrinology, vol. 44, no. 1, 1986, pages 15-21

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PN0380	SERIAL NO. 10/559,886
O I P E JUL 24 2006 IAP19 PATENT & TRADEMARK OFFICE		APPLICANT Alan Cuthbertson, et.al.	
		FILING DATE To be assigned	GROUP To be assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Shigematsu K, et.al., "Autoradiographic evidence of angiotensin II binding sites in the human adrenal gland" Biomedical Research 1988 Japan, vol. 9, no. 1, 1988, pages 27-31
	Speth R.C. et.al. "Angiotensin II receptor localization in the canine CNS" Brain Research 1985 Netherlands, vol. 326, no. 1, 1985, pages 137-143
	Bagby Susan P, et.al. "Ang II AT(1) and AT(2) receptors in developing kidney of normal microswine" American Journal of Physiology. Renal Physiology. Oct. 2002, vol. 283, no. 4, Oct. 2002, pages F755-F764
	Heppeler A. et.al., "Receptor targeting for tumor localization and therapy with radiopeptides" Current Medicinal Chemistry, Bentham Science publishers BV, BE, vol. 7, no. 9, 2000, pages 971-994
	Henze M, et.al. "PET imaging of somatostatin receptors using" Journal of Nuclear Medicine, New York, NY vol. 42, no. 7 pages 1053-1056
	Int'l Search Report and Written Opinion PCT/NO2004/000335 dated March 2006

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.